journal
MENU ▼
Read by QxMD icon Read
search

Lung Cancer: Journal of the International Association for the Study of Lung Cancer

journal
https://www.readbyqxmd.com/read/28709627/plasma-concentration-of-osimertinib-in-a-non-small-cell-lung-cancer-patient-with-chronic-renal-failure-undergoing-hemodialysis
#1
LETTER
Tomohiro Tamura, Yuki Takagi, Hatsumi Okubo, Shozaburo Yamaguchi, Yasuko Kikkawa, Ikuta Hashimoto, Takayuki Kaburagi, Masatomo Miura, Hiroaki Satoh, Nobuyuki Hizawa
No abstract text is available yet for this article.
July 8, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28648688/association-of-diffuse-idiopathic-pulmonary-neuroendocrine-cell-hyperplasia-dipnech-with-lung-adenocarcinoma-a-radiologist-s-perspective
#2
LETTER
Luis Gorospe, Gemma María Muñoz-Molina, Frank Eric Farfán-Leal, Alberto Cabañero-Sánchez, Isabel García-Gómez-Muriel, Amparo Benito-Berlinches
No abstract text is available yet for this article.
June 19, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28623058/supraclavicular-schwannoma-mimicking-a-lymphadenopathy-in-a-lung-cancer-patient-pet-ct-findings
#3
LETTER
Luis Gorospe, María Eugenia Rioja-Martín, Astrid Lucía Santos-Carreño, Rubén Eduardo Pacios-Blanco, Gemma María Muñoz-Molina
No abstract text is available yet for this article.
June 8, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28624125/do-protons-have-a-role-in-the-treatment-of-locally-advanced-nsclc-with-radiotherapy
#4
EDITORIAL
Fiona McDonald, Gerard G Hanna
No abstract text is available yet for this article.
May 30, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28526140/thymic-malignancies-twisting-between-autoimmunity-and-immunotherapy
#5
EDITORIAL
Nicolas Girard
No abstract text is available yet for this article.
May 11, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28457608/corrigendum-to-prognosis-in-advanced-lung-cancer-a-prospective-study-examining-key-clinicopathological-factors-lung-cancer-88-2015-304-309
#6
Claribel P Simmons, Filippos Koinis, Marie T Fallon, Kenneth C Fearon, Jo Bowden, Tora S Solheim, Bjorn Henning Gronberg, Donald C McMillan, Ioannis Gioulbasanis, Barry J Laird
No abstract text is available yet for this article.
April 27, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28457607/erratum-to-frequent-methylation-and-oncogenic-role-of-microrna-34b-c-in-small-cell-lung-cancer-lung-cancer-76-1-2012-32-38
#7
Norimitsu Tanaka, Shinichi Toyooka, Junichi Soh, Takafumi Kubo, Hiromasa Yamamoto, Yuho Maki, Takayuki Muraoka, Kazuhiko Shien, Masashi Furukawa, Tsuyoshi Ueno, Hiroaki Asano, Kazunori Tsukuda, Keisuke Aoe, Shinichiro Miyoshi
No abstract text is available yet for this article.
April 27, 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676222/optimal-management-of-egfr-mutant-non-small-cell-lung-cancer-with-disease-progression-on-first-line-tyrosine-kinase-inhibitor-therapy
#8
REVIEW
Bin-Chi Liao, Chia-Chi Lin, Jih-Hsiang Lee, James Chih-Hsin Yang
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been approved as standard first-line treatments for advanced EGFR-mutant non-small cell lung cancer (NSCLC) based on superior progression-free survival results compared to platinum doublet chemotherapy regimens. Acquired resistance to an EGFR-TKI inevitably develops after a period of effective drug treatment. After tumor progression, many combination therapy regimens that include an EGFR-TKI, or EGFR-TKI monotherapy, have been tested in prospective trials with the aim of extending survival...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676221/myc-expression-correlates-with-pd-l1-expression-in-non-small-cell-lung-cancer
#9
Eun Young Kim, Arum Kim, Se Kyu Kim, Yoon Soo Chang
Objectives Programmed death-ligand 1 (PD-L1) is a widely used biomarker for predicting immune checkpoint inhibitors, but is of limited usefulness in the prediction of drug response. MYC, a transcription factor that is overexpressed in cancers, is involved in preventing immune cells from attacking tumor cells through inducing PD-L1 expression. This study evaluated the relationship between MYC and PD-L1 expression in 84 non-small cell lung cancer (NSCLC) patients who underwent curative surgical resection. Materials and Methods The relationship between MYC and PD-L1 was investigated by introducing pcDNA3-cMYC into A549 and H1299 cells with low PD-L1 expression and siRNA against MYC into H60 and H2009 cells with high PD-L1 expression...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676220/comparing-the-effects-of-afatinib-with-gefitinib-or-erlotinib-in-patients-with-advanced-stage-lung-adenocarcinoma-harboring-non-classical-epidermal-growth-factor-receptor-mutations
#10
Yi-Cheng Shen, Guan-Chin Tseng, Chih-Yeh Tu, Wei-Chun Chen, Wei-Chih Liao, Wei-Cheng Chen, Chia-Hsiang Li, Hung-Jen Chen, Te-Chun Hsia
OBJECTIVE: Approximately 10%-15% patients with epidermal growth factor receptor (EGFR) mutations harbor non-classical mutations. However, the effects of EGFR-tyrosine kinases (TKIs), particularly second-generation EGFR-TKI (afatinib) compared to first-generation EGFR-TKIs (gefitinib/erlotinib), in patients with non-classical EGFR mutations remain unknown. METHODS: We conducted this retrospective study at the China Medical University Hospital (Taichung, Taiwan) from June 2011 to July 2016...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676219/de-novo-cystic-brain-lesions-mimicking-neurocysticercosis-in-alk-positive-lung-cancer
#11
Su-Hyun Kim, Jae-Won Hyun, Ho Jin Kim, Ho-Shin Gwak, Sang Hyun Lee, Eun-Kyung Hong, Youngjoo Lee
Cystic brain metastases (CBM) have been recently reported in a minority of patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). All previously reported ALK-positive CBM developed during crizotinib treatment and were often asymptomatic and indolent, even without CNS-directed therapy. Thus, crizotinib was suggested as an etiologic agent for the development of CBM. Here, we report a case of de novo CBM in a patient with ALK-positive NSCLC prior to crizotinib treatment; the ALK-positive NSCLC had initially been misdiagnosed as neurocysticercosis because of the atypical radiological presentation of brain metastases...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676218/gtf2i-mutation-frequently-occurs-in-more-indolent-thymic-epithelial-tumors-and-predicts-better-prognosis
#12
Yanfen Feng, Yiyan Lei, Xiaoyan Wu, Yuhua Huang, Huilan Rao, Yu Zhang, Fang Wang
OBJECTIVES: A missense mutation in GTF2I was previously identified in thymic epithelioid tumor (TET). However, the clinicopathological relevance of GTF2I mutation has not been illustrated. We studied the prognostic importance of GTF2I mutation as well as its relation to histological subtypes in a large number of TETs. METHODS: TET samples from 296 patients with clinical and follow-up data were collected, and histological subtypes were classified. Analysis of the GTF2I (chromosome 7 c...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676217/calcium-plus-vitamin-d-supplementation-and-lung-cancer-incidence-among-postmenopausal-women-in-the-women-s-health-initiative
#13
Meng-Hua Tao, Qi Dai, Shande Chen, Jo L Freudenheim, Thomas Rohan, Heather Wakelee, Mridul Datta, Jean Wactawski-Wende
BACKGROUND: Magnesium and calcium are antagonistic in many physiologic processes. However, few studies have investigated the associations of supplemental calcium with lung cancer risk taking this antagonism into account. We evaluated the effect of calcium and vitamin D supplementation on lung cancer incidence and explored whether the ratio of baseline calcium to magnesium (Ca:Mg) intake modifies the association in the Women's Health Initiative (WHI) calcium plus vitamin D supplementation (CaD) trial...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676216/functional-analysis-of-discoidin-domain-receptor-2-mutation-and-expression-in-squamous-cell-lung-cancer
#14
Naomi Kobayashi-Watanabe, Akemi Sato, Tatsuro Watanabe, Tomonori Abe, Chiho Nakashima, Eisaburo Sueoka, Shinya Kimura, Naoko Sueoka-Aragane
OBJECTIVES: Discoidin domain receptor (DDR) 2 mutations have recently been reported to be candidate targets of molecular therapy in lung squamous cell carcinoma (SQCC). However, the status of DDR2 expression and mutations, as well as their precise roles in lung SQCC, have not been clarified. We here report DDR2 mutation and expression status in clinical samples and its role of lung SQCC. MATERIALS AND METHODS: We investigated DDR2 expression and mutation status in 44 human clinical samples and 7 cell lines...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676215/identification-of-a-novel-t1151k-alk-mutation-in-a-patient-with-alk-rearranged-nsclc-with-prior-exposure-to-crizotinib-and-ceritinib
#15
Viola W Zhu, J Jean Cui, Maria Fernandez-Rocha, Alexa B Schrock, Siraj M Ali, Sai-Hong Ignatius Ou
Patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) derive significant clinic benefit from treatment with ALK inhibitors. Crizotinib was the first approved tyrosine kinase inhibitor (TKI) for this distinct molecular subset of NSCLC. Disease progression on TKI inevitably arises secondary to diverse resistance mechanisms among which emergence of secondary ALK mutations is one of many ways in which tumor cells have adapted to survive. Therefore there is a clinical imperative to identify acquired ALK mutations via repeat tissue biopsy if clinically feasible...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676214/dna-mismatch-repair-deficiency-in-surgically-resected-lung-adenocarcinoma-microsatellite-instability-analysis-using-the-promega-panel
#16
Kazuya Takamochi, Fumiyuki Takahashi, Yoshiyuki Suehara, Eiichi Sato, Shinji Kohsaka, Takuo Hayashi, Shigehisa Kitano, Toshihide Uneno, Shinya Kojima, Kengo Takeuchi, Hiroyuki Mano, Kenji Suzuki
OBJECTIVES: DNA mismatch repair (MMR) deficiency has recently received increasing attention as a significant biomarker to predict the treatment effect of immune checkpoint inhibitors for various malignant neoplasms. To evaluate MMR status, we analyzed the microsatellite instability (MSI) of lung adenocarcinomas. MATERIALS AND METHODS: Frozen tissues of lung adenocarcinoma and corresponding normal lung were obtained from 341 patients, including 141 with tumors harboring driver gene alterations (50 EGFR gene mutations, 50 KRAS gene mutations, 21 ALK fusions, 10 ROS1 fusions, and 10 RET fusions) and 200 with pan-negative tumors (100 never- or light-smokers and 100 heavy-smokers), who were surgically treated between 2007 and 2015...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676213/urine-circulating-tumor-dna-ctdna-detection-of-acquired-egfr-t790m-mutation-in-non-small-cell-lung-cancer-an-outcomes-and-total-cost-of-care-analysis
#17
Jacob Sands, Qianyi Li, John Hornberger
OBJECTIVES: Third-generation tyrosine kinase inhibitors (TKIs) have proven effective in patients with the acquired EGFR T790M resistance mutation who progress on prior EGFR TKI therapy. Median progression-free survival (PFS) on a 3rd-gen TKI was 9-10 months for T790M+ patients compared to 2.8 months for T790M- patients. PFS is similar regardless of the specimen used to assess T790M, such as tissue, plasma, or urine ctDNA. This study aimed to assess the total cost of care of a urine-testing strategy (UTS) versus a tissue-testing strategy (TTS) for T790M detection, in patients with EGFR-mutation positive lung adenocarcinoma and progression on prior TKI therapy...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676212/patterns-of-care-and-outcomes-for-stage-iiib-non-small-cell-lung-cancer-in-the-tnm-7-era-results-from-the-netherlands-cancer-registry
#18
C Dickhoff, M Dahele, E F Smit, M A Paul, S Senan, K J Hartemink, R A Damhuis
OBJECTIVES: There is limited data on the pattern of care for locally advanced, clinical (c) IIIB non-small cell lung cancer (NSCLC) in the TNM-7 staging era. The primary aim of this study was to investigate national patterns of care and outcomes in the Netherlands, with a secondary focus on the use of surgery. MATERIAL AND METHODS: Data from patients treated for TNM-7 cIIIB NSCLC between 2010 and 2014, was extracted from the Netherlands Cancer Registry (NCR). Survival data was obtained from the automated Civil Registry...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28676211/cost-effectiveness-analysis-of-additional-bevacizumab-to-pemetrexed-plus-cisplatin-for-malignant-pleural-mesothelioma-based-on-the-maps-trial
#19
Mei Zhan, Hanrui Zheng, Ting Xu, Yu Yang, Qiu Li
PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy, and pemetrexed/cisplatin (PC) is the gold standard first-line regime. This study evaluated the cost-effectiveness of the addition of bevacizumab to PC (with maintenance bevacizumab) for unresectable MPM based on a phase III trial that showed a survival benefit compared with chemotherapy alone. METHODS: To estimate the incremental cost-effectiveness ratio (ICER) of the incorporation of bevacizumab, a Markov model based on the MAPS trial, including the disease states of progression-free survival, progressive disease and death, was used...
August 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/28577958/lepidic-predominant-adenocarcinoma-and-invasive-mucinous-adenocarcinoma-of-the-lung-exhibit-specific-mucin-expression-in-relation-with-oncogenic-drivers
#20
Duruisseaux Michaël, Antoine Martine, Rabbe Nathalie, Rodenas Anita, Mc Leer-Florin Anne, Lacave Roger, Poulot Virginie, Duchêne Belinda, Van Seuningen Isabelle, Cadranel Jacques, Wislez Marie
OBJECTIVES: To evaluate MUC1, MUC2, MUC5B, MUC5AC, and MUC6 expression in invasive lepidic predominant adenocarcinoma (LPA) and invasive mucinous adenocarcinoma (IMA) of the lung, and the impact of oncogenic drivers. MATERIALS AND METHODS: MUC1, MUC2, MUC5B, MUC5AC, MUC6, TTF1 and Hnf4α immunohistochemistry was performed on surgical samples from 52 patients with IMA (n=25) or LPA (n=27). We searched for EGFR, KRAS, BRAF, and HER2 mutations and ALK, ROS1, and NRG1 rearrangements...
July 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
journal
journal
29732
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"